{"product_id":"skhb-pestle-analysis","title":"Shanghai Kehua Bio-engineering PESTLE Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eYour Competitive Advantage Starts with This Report\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eOur PESTLE Analysis of Shanghai Kehua Bio-engineering highlights the political, economic, social, technological, legal and environmental forces shaping its growth trajectory and risk profile, delivering concise, actionable intelligence for investors and strategists. Use these expert insights to identify opportunities, anticipate regulatory shifts, and refine competitive strategy. Purchase the full report for the complete, editable analysis and data-driven recommendations.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eolitical factors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHealthcare policy priorities\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eChina’s Healthy China 2030 drive and post‑COVID focus on public health and diagnostics has expanded demand for IVDs, with the national health budget rising and health expenditure approaching 7% of GDP by 2023, fueling central and provincial procurement for hospitals and blood banks. Policy shifts toward early detection and prevention favor vendors offering broad test menus and integrated solutions. Relative stability in health spending supports multi‑year product roadmaps and predictable adoption cycles for Shanghai Kehua.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory direction NMPA\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNMPA moves to expand priority review and conditional approvals for clinically valuable assays have shortened time-to-market, with select expedited reviews completed in roughly 6 months for high-priority submissions; this bolsters Shanghai Kehua’s launch speed. Stricter quality and strengthened post-market surveillance since 2021 raise compliance and CAPEX\/OPEX burdens. Local clinical-trial and real-world-evidence requirements shape launch sequencing and market access. Faster emergency pathways used during COVID created surge sales opportunities.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLocalization and self-reliance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eGovernment pushes for localization and self-reliance boost domestic IVD makers like Shanghai Kehua: Beijing’s industrial policies and procurement guidelines increasingly favor homegrown technologies that meet performance standards, while central and local subsidies plus R\u0026amp;D tax incentives support innovation; China’s R\u0026amp;D intensity reached about 2.5% of GDP in 2023, reinforcing policies aimed at reducing import dependence by 2025.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePublic procurement dynamics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eHospital tendering and centralized purchasing in China increasingly dictate pricing power for diagnostic firms; since 2020 volume-based procurement pilots have been extended from drugs to medical devices and several IVD categories in provincial pilots, intensifying price pressure. Transparent bidding and public procurement platforms raise competition but favor scalable, cost-effective assay platforms that demonstrate low per-test cost and high throughput. Long tender cycles, typically 6–18 months, require Shanghai Kehua to maintain a robust product pipeline and inventory planning to avoid revenue volatility.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePricing pressure: centralized tenders drive down margins\u003c\/li\u003e\n\u003cli\u003eVBP expansion: provincial IVD pilots since 2020\u003c\/li\u003e\n\u003cli\u003eTransparency: rewards cost-effective platforms\u003c\/li\u003e\n\u003cli\u003eTender cycles 6–18 months: need strong pipeline\/inventory\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTrade and export conditions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eGeopolitical frictions raise risks for Shanghai Kehua Bio-engineering by complicating component sourcing and export licenses, while export growth hinges on meeting target markets’ regulatory expectations; China medical device exports exceeded US$50bn in 2024, increasing scrutiny and compliance costs.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eTariffs\/non-tariff barriers reduce margins on instruments and reagents\u003c\/li\u003e\n\u003cli\u003eDiversified supply chains cut cross-border volatility\u003c\/li\u003e\n\u003cli\u003eRegulatory alignment drives export access\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHealthy China lifts IVD demand: \u003cstrong\u003e~7%\u003c\/strong\u003e GDP, faster approvals, price pressure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHealthy China 2030 and ~7% health expenditure of GDP in 2023 drive IVD demand and predictable hospital procurement. NMPA expedited reviews (~6 months for priority) shorten launches but tightened post‑market rules raise compliance costs. Localization policies and R\u0026amp;D at ~2.5% GDP (2023) plus \u0026gt;US$50bn medical device exports (2024) push domestic scaling and export scrutiny. Centralized tenders (6–18m cycles) compress margins.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eFactor\u003c\/th\u003e\n\u003cth\u003eImpact\u003c\/th\u003e\n\u003cth\u003eKey metric\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eHealth policy\u003c\/td\u003e\n\u003ctd\u003eHigher demand\u003c\/td\u003e\n\u003ctd\u003eHealth spend ~7% GDP (2023)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRegulation\u003c\/td\u003e\n\u003ctd\u003eFaster launch, higher compliance\u003c\/td\u003e\n\u003ctd\u003eExpedited ~6m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLocalization\u003c\/td\u003e\n\u003ctd\u003eSupport for domestic firms\u003c\/td\u003e\n\u003ctd\u003eR\u0026amp;D ~2.5% GDP (2023)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eProcurement\u003c\/td\u003e\n\u003ctd\u003ePrice pressure\u003c\/td\u003e\n\u003ctd\u003eTender cycles 6–18m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eProvides a targeted PESTLE overview of how Political, Economic, Social, Technological, Environmental, and Legal forces specifically impact Shanghai Kehua Bio-engineering, identifying risks and growth levers. Each dimension is linked to current data and forward-looking implications for executives and investors.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eProvides a concise PESTLE snapshot of Shanghai Kehua Bio‑engineering to relieve due‑diligence pain points, supporting quick alignment on external risks and market positioning during planning sessions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eE\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003economic factors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMacroeconomic growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eChina's steady GDP (5.2% in 2023) and rising health spending (public health ~7.1% of GDP in 2022; gov't health outlays up ~6% YoY in 2023) support diagnostics utilization, while economic slowdowns can delay capital instrument purchases but leave reagent pull-through intact. Urbanization (65.2% urban in 2023) expands hospital and lab capacity, and fiscal budget cycles drive booking visibility fluctuations.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHealthcare funding mix\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eChina’s public insurance covers over 95% of the population, and DRG-style payment pilots in more than 2,000 hospitals by 2023 are reshaping test volumes and case-mix toward cost-weighted diagnostics. Private hospitals, which held about 22% of hospital beds in 2022, and premium care segments drive uptake of higher-margin companion diagnostics and specialty assays. Recent 2023–24 reimbursement reviews have repriced many routine tests downward while favoring high clinical-value assays, and cash flow for companies like Shanghai Kehua hinges on receivables from large hospital systems that generate roughly 70% of inpatient revenue.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCost structure pressures\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eInput costs for enzymes, antigens, plastics and electronics directly drive COGS for Shanghai Kehua, with raw materials typically representing a large share of production spend; RMB volatility (about 5% vs USD through 2024) raises imported-material costs and can boost export competitiveness when weaker. High-volume reagent production can lift gross margins by several hundred basis points through economies of scale, while lean manufacturing and automation reduce per-unit costs and improve cost resilience.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMarket competition intensity\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eGlobal brands such as Thermo Fisher, Roche and Abbott alongside fast-growing domestic peers increase price pressure on Shanghai Kehua, while platform lock-in and broader reagent menus raise switching costs for clinical labs.\u003c\/p\u003e\n\u003cp\u003eAfter-sales service performance and uptime guarantees have become decisive purchase criteria, and ongoing consolidation of hospital and third-party labs strengthens customer bargaining leverage.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCompetitive intensity: global and domestic rivals\u003c\/li\u003e\n\u003cli\u003eSwitching costs: platform lock-in, menu breadth\u003c\/li\u003e\n\u003cli\u003eDifferentiators: service, uptime guarantees\u003c\/li\u003e\n\u003cli\u003eBuyer power: lab consolidation\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eExport market opportunities\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eEmerging markets—where about half the global population still lacks adequate diagnostic access—favor affordable, reliable platforms, positioning Shanghai Kehua to expand in SEA and Africa; Asia-Pacific IVD demand grew strongly through 2024. Currency stability and strong local distributors accelerate adoption, while typical registration timelines of 6–18 months shape overseas revenue ramps. Portfolio localization boosts tender win rates and long-term market share.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eaccess: ~50% underserved\u003c\/li\u003e\n\u003cli\u003eregistration: 6–18 months\u003c\/li\u003e\n\u003cli\u003eimportance: distributor strength\u003c\/li\u003e\n\u003cli\u003elocalization: higher tender success\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHealthy China lifts IVD demand: \u003cstrong\u003e~7%\u003c\/strong\u003e GDP, faster approvals, price pressure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eChina GDP 5.2% (2023); health spend ~7.1% of GDP (2022) supports diagnostics demand. Public insurance covers \u0026gt;95%; DRG pilots in \u0026gt;2,000 hospitals (2023) shift test mix toward cost-weighted assays. Private hospitals ~22% of beds (2022); RMB volatility ~5% vs USD through 2024 affects imported COGS. Emerging markets ~50% underserved; registration 6–18 months.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eChina GDP (2023)\u003c\/td\u003e\n\u003ctd\u003e5.2%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHealth spend (2022)\u003c\/td\u003e\n\u003ctd\u003e~7.1% GDP\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePublic insurance\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;95%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDRG pilots (2023)\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;2,000 hospitals\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePrivate beds (2022)\u003c\/td\u003e\n\u003ctd\u003e~22%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRMB vol. (thru 2024)\u003c\/td\u003e\n\u003ctd\u003e~5% vs USD\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUnderserved markets\u003c\/td\u003e\n\u003ctd\u003e~50%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRegistration\u003c\/td\u003e\n\u003ctd\u003e6–18 months\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eFull Version Awaits\u003c\/span\u003e\u003cbr\u003eShanghai Kehua Bio-engineering PESTLE Analysis\u003c\/h2\u003e\n\u003cp\u003eThe Shanghai Kehua Bio-engineering PESTLE analysis you see here is the exact document you’ll receive after purchase—fully formatted and ready to use. It provides concise political, economic, social, technological, legal, and environmental insights specific to the company and sector. No placeholders or teasers—this preview is the real, finished file you’ll download immediately after payment.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"PortersFiveForce","offers":[{"title":"Default Title","offer_id":56162447294841,"sku":"skhb-pestle-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0914\/5276\/8633\/files\/skhb-pestle-analysis.png?v=1762701002","url":"https:\/\/portersfiveforce.com\/products\/skhb-pestle-analysis","provider":"Porter's Five Forces","version":"1.0","type":"link"}